Abstract
Background: In the present study, a new assay for the measurement of glial fibrillary acidic protein (GFAP) in human blood is described. The aim of the study was to present the characteristics of a new GFAP assay for blood analysis. Methods: The method, a newly developed enzyme-linked immunosorbent assay (ELISA), was validated using blood samples from healthy blood donors and from patients with severe traumatic brain injury (TBI). Results: 22 out of 72 healthy blood donors had a detectable GFAP level. The reference values (percentiles) are as follows: P50=0.15 μg/l and P95=0.49 μg/l; range 0.15–0.76 μg/l. Conclusions: GFAP in blood might be a promising new marker for astrocyte involvement after acute brain damage.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
